Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (previously presented) An isolated EG-VEGF polypeptide comprising at least 95% amino acid sequence identity with residues 20 to 105 of SEQ ID NO:2, wherein the polypeptide promotes proliferation of adrenal cortex-derived capillary endothelial cells.

2-5. (cancelled)

- 6. (previously presented) The isolated polypeptide of claim 1, comprising amino acid residues 20 to 105 of SEQ ID NO:2.
- 7. (previously presented) An isolated EG-VEGF polypeptide comprising at least 95% amino acid sequence identity to SEQ ID NO:2, wherein the polypeptide promotes proliferation of adrenal cortex-derived capillary endothelial cells.
- 8. (previously presented) The isolated polypeptide of claim 7, comprising the amino acid sequence of SEQ ID NO:2.

9-11. (cancelled)

12. (previously presented) The polypeptide of claim 1, wherein the polypeptide sequence is a human sequence.

13-29. (cancelled)

2

U.S. Patent Application Serial No. 10/692,299

Amendment dated April 11, 2008

Reply to Office Action of December 31, 2007

- 30. (previously presented) A chimeric polypeptide comprising the polypeptide of claim 1 fused to a heterologous polypeptide.
- 31. (previously presented) A chimeric polypeptide comprising the polypeptide of claim 6 fused to a heterologous polypeptide.
- 32. (previously presented) A chimeric polypeptide comprising the polypeptide of claim 7 fused to a heterologous polypeptide.
- 33. (previously presented) A chimeric polypeptide comprising the polypeptide of claim 8 fused to a heterologous polypeptide.
- 34. (previously presented) The chimeric polypeptide of claim 30, wherein said heterologous polypeptide is an Fc portion of an immunoglobulin or a HIS tag.
- 35. (previously presented) The chimeric polypeptide of claim 31, wherein said heterologous polypeptide is an Fc portion of an immunoglobulin or a HIS tag.
- 36. (previously presented) The chimeric polypeptide of claim 32, wherein said heterologous polypeptide is an Fc portion of an immunoglobulin or a HIS tag.
- 37. (previously presented) The chimeric polypeptide of claim 33, wherein said heterologous polypeptide is an Fc portion of an immunoglobulin or a HIS tag.